Financial Performance - The company's revenue for Q3 2021 reached ¥296,130,931.33, representing a year-on-year increase of 115.35%[5] - Net profit attributable to shareholders for the same period was ¥98,776,619.60, up 129.72% compared to the previous year[5] - The basic earnings per share for Q3 2021 was ¥1.71, reflecting an increase of 131.08% year-on-year[6] - Total operating revenue for the first three quarters of 2021 reached ¥606,591,150.96, a significant increase from ¥319,540,960.44 in the same period of 2020, representing an increase of approximately 89.9%[19] - Net profit for the first three quarters of 2021 was ¥200,619,524.75, up from ¥93,779,491.23 in 2020, indicating a growth of approximately 113.4%[21] - The total comprehensive income for the third quarter of 2021 was CNY 190,621,471.44, compared to CNY 93,779,491.23 in the same period of 2020, representing an increase of 103.5%[22] - Basic and diluted earnings per share for Q3 2021 were CNY 3.47, up from CNY 1.62 in Q3 2020, reflecting a growth of 114.2%[22] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥1,576,907,500.35, a growth of 33.37% from the previous year[6] - The total assets as of the end of the third quarter of 2021 amounted to ¥1,576,907,500.35, compared to ¥1,182,374,890.54 at the end of the previous year, marking an increase of about 33.4%[17] - Total liabilities as of the end of the third quarter of 2021 were ¥437,534,048.14, up from ¥207,768,377.74 in the previous year, which is an increase of approximately 110.9%[17] - The company's fixed assets were valued at ¥514,884,937.70, compared to ¥351,455,661.48 in the previous year, reflecting an increase of about 46.5%[17] - Total liabilities amounted to 207,768,377.74, with current liabilities at 192,200,265.44[28] - Non-current liabilities totaled 15,568,112.30, including deferred income of 11,669,186.06 and deferred tax liabilities of 3,898,926.24[28] Cash Flow - The net cash flow from operating activities was ¥336,714,681.17, an increase of 265.54% compared to the same period last year[6] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 554,609,430.46, significantly higher than CNY 239,304,252.47 in the same period of 2020, marking an increase of 131.7%[24] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 336,714,681.17, compared to CNY 92,113,454.12 in 2020, indicating a growth of 264.5%[24] - The net cash flow from investment activities for the first three quarters of 2021 was -CNY 185,925,680.02, a decrease from CNY 113,788,066.39 in 2020[24] - The net cash flow from financing activities for the first three quarters of 2021 was -CNY 70,730,847.22, compared to -CNY 91,925,769.50 in 2020, showing an improvement of 23.0%[25] Research and Development - Research and development expenses totaled ¥11,267,299.30, which is 3.80% of revenue, marking an increase of 0.41 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2021 totaled ¥28,002,405.20, compared to ¥11,464,272.78 in 2020, indicating an increase of approximately 144.4%[19] Equity - The total equity attributable to shareholders was ¥1,139,373,452.21, reflecting a year-on-year increase of 16.91%[6] - The total equity attributable to shareholders of the parent company was ¥1,139,373,452.21, up from ¥974,606,512.80 in the previous year, indicating an increase of approximately 16.9%[17] Operational Insights - The company attributed revenue growth to the gradual release of new production capacity and optimization of product structure[9] - The company completed the construction and commissioning of new production lines in the first half of 2021, contributing to increased capacity and revenue[9] - The company reported a significant increase in sales revenue, with cash received from sales of goods and services amounting to CNY 516,069,512.01 for the first three quarters of 2021, compared to CNY 225,407,141.34 in 2020, an increase of 129.0%[23] Future Outlook - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[14] - There were no significant mergers or acquisitions reported in the third quarter of 2021[14] - The company did not provide specific future guidance or outlook for the upcoming quarters[14] - The company has implemented new leasing standards starting from 2021, which may impact financial reporting and asset management strategies moving forward[26]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[14]. - The company's operating revenue for the first half of the year reached approximately CNY 310.46 million, representing a 70.56% increase compared to the same period last year[22]. - The net profit attributable to shareholders increased by 100.56% year-on-year, amounting to approximately CNY 101.84 million[22]. - Basic earnings per share rose to CNY 1.76, a 100% increase from the previous year[23]. - The net cash flow from operating activities surged by 280.01%, reaching approximately CNY 158.99 million[22]. - The company's oxygen business generated sales revenue of CNY 178.84 million, with healthcare oxygen molecular sieve sales accounting for approximately 37.28% of total revenue[87]. - The sales revenue of hydrogen molecular sieves reached CNY 22.77 million in the first half of 2021, representing a year-on-year growth of 86.38%[87]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to molecular sieves and gas separation[14]. - The company's R&D investment as a percentage of operating revenue increased to 5.39%, up from 3.74% in the previous year, marking a 1.65 percentage point increase[21]. - The company has achieved a significant increase in R&D investment, with total R&D expenses amounting to ¥16,735,105.90, a 146.07% increase compared to the previous period[68]. - The average salary of R&D personnel increased significantly to ¥150,758.66, compared to ¥45,808.97 in the previous period, indicating a focus on talent retention and motivation[77]. - The company holds a total of 20 authorized invention patents and 50 utility model patents as of the report date, with a total of 94 intellectual property rights[66]. Market Expansion and Strategy - Future outlook includes a projected revenue growth of 25% for the full year 2021, driven by market expansion and new product launches[14]. - Market expansion efforts include entering Southeast Asian markets, with an expected revenue contribution of RMB 30 million in 2022[14]. - The company is actively expanding its capacity in Southeast Asia to support its international development strategy, with projects expected to be completed by the end of 2021[89]. - The company aims to improve its market position and product structure to compete with international giants like Honeywell UOP and Arkema[63]. Product Development and Innovation - The company plans to launch two new products in Q3 2021, which are expected to contribute an additional RMB 100 million in revenue[14]. - The company is advancing projects in environmental governance and energy chemical fields, focusing on the development of catalysts and adsorbents for various applications[90]. - The company has developed core technologies for producing molecular sieves from raw powder to formed products, enhancing brand recognition and market share against competitors[42]. - The company is focusing on high-value-added products, particularly in the oxygen production sector, with successful applications in large-scale VPSA oxygen production projects[86]. Financial Position and Assets - The total assets of the company at the end of the reporting period were approximately CNY 1.33 billion, a 12.14% increase from the end of the previous year[22]. - The net assets attributable to shareholders increased by 6.75% to approximately CNY 1.04 billion[22]. - The company's total current assets amounted to ¥710,675,461.70, a slight decrease from ¥717,715,430.63 at the end of 2020, representing a decrease of approximately 1.5%[196]. - The cash and cash equivalents were reported at ¥258,980,163.03, an increase from ¥142,665,624.88 in December 2020, indicating a growth of approximately 81.5%[196]. - The total fixed assets reached ¥415,659,704.14, up from ¥351,455,661.48, marking an increase of approximately 18.3%[196]. Environmental and Social Responsibility - The company has implemented advanced environmental protection facilities, reducing production costs and pollutant emissions through recycling processes[83]. - The company has achieved a green coverage area of 31,358.9 m², representing a green coverage rate of 37.38% of the outdoor area[126]. - The company has actively participated in social welfare, providing 33,400 yuan in aid to the elderly and donating 4,000 yuan to impoverished families[128]. - The company invested 504,000 yuan in the repair of community roads to enhance local infrastructure[129]. Shareholder Commitments and Governance - The company reported a commitment from major shareholders, including the actual controller, to not transfer or delegate management of shares held prior to the IPO for 36 months[134]. - Shareholders are restricted from transferring more than 25% of their shares annually while serving as directors or senior management, and for six months post-departure[136]. - The company has established a commitment to not repurchase shares held prior to the IPO during the specified lock-up periods[138]. - Major shareholders, including the actual controller, have made commitments regarding share transfers and management during their tenure[139]. Risks and Challenges - The company faces risks related to product iteration, technology commercialization, and potential loss of core technical personnel, which could impact its competitive position[93]. - The domestic molecular sieve industry faces challenges in technology maturity and market application compared to developed countries, but opportunities for growth are increasing[33].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[14]. - The company's operating revenue for the first half of the year reached approximately CNY 310.46 million, representing a 70.56% increase compared to the same period last year[22]. - The net profit attributable to shareholders increased by 100.56% year-on-year, amounting to approximately CNY 101.84 million[22]. - Basic earnings per share rose to CNY 1.76, a 100% increase from CNY 0.88 in the previous year[23]. - The net cash flow from operating activities surged by 280.01%, reaching approximately CNY 158.99 million, driven by increased sales revenue[22]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2021, driven by increased demand in the industrial sector[14]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[14]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[14]. - The company is actively expanding its capacity layout in Southeast Asia to support its international development strategy[87]. - The company aims to expand its market share by enhancing its brand and leveraging its manufacturing advantages to compete with international molecular sieve enterprises[81]. Research and Development - The company has allocated RMB 100 million for research and development in advanced materials technology for the upcoming fiscal year[14]. - The company's R&D investment as a percentage of operating revenue increased to 5.39%, up from 3.74% in the previous year, reflecting a 1.65 percentage point increase[21]. - The company has achieved a significant increase in R&D investment, with total R&D expenses amounting to ¥16,735,105.90, a 146.07% increase compared to the previous period[67]. - The company is focusing on new product development, including a new type of molecular sieve for hydrogen purification and specialized activated powders for polyurethane adhesives[71]. - The company has established a comprehensive innovation system and increased R&D investment to achieve breakthroughs in core technologies through independent and collaborative research[32]. Product Development and Technology - New product development includes the launch of a high-efficiency molecular sieve, expected to increase production capacity by 40%[14]. - The company has developed core technologies for producing molecular sieves from raw powder to formed products, enhancing brand recognition and market share against competitors[42]. - The company is focusing on high-value-added products, particularly in the oxygen production sector, with successful applications in large-scale VPSA oxygen production projects[84]. - The company is advancing the development of molecular sieves for environmental governance, including products for flue gas denitrification and nuclear wastewater treatment[51]. Environmental and Social Responsibility - The company has established a wastewater treatment station to manage production wastewater, employing various treatment processes to ensure compliance with environmental standards[117]. - The company has implemented pollution control facilities, including cyclone separators and low-nitrogen burners, to treat emissions before discharge[116]. - The company has actively participated in social welfare, providing 33,400 yuan in aid to the elderly and donating 4,000 yuan to impoverished families[125]. - The company has committed to fulfilling various promises related to share restrictions and compliance with regulations[130]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions and fluctuating raw material prices, which could impact future performance[14]. - The company is facing risks related to product iteration, technology commercialization, and potential loss of core technical personnel, which could impact its competitive position[91]. - The domestic molecular sieve industry faces challenges in technology maturity and market application compared to developed countries, but there are opportunities for growth due to increasing domestic demand[33]. Shareholder and Corporate Governance - The company guarantees that its IPO prospectus and related documents do not contain false statements or omissions, taking legal responsibility for their accuracy and completeness[24]. - The company has established a lock-up period of at least 6 months if the stock price falls below the IPO price for 20 consecutive trading days[134]. - Shareholders are restricted from transferring more than 25% of their shares annually during their tenure as directors or senior management[133]. - The company must announce specific reduction situations within 2 trading days after the completion of the share reduction plan[144].

Financial Performance - The company's operating revenue for 2020 was approximately CNY 451.55 million, representing an increase of 11.23% compared to 2019[24]. - Net profit attributable to shareholders increased by 48.10% to CNY 127.37 million, while the net profit after deducting non-recurring gains and losses rose by 59.71% to CNY 109.23 million[24][26]. - Basic earnings per share rose to CNY 2.20, a 13.99% increase year-on-year, reflecting the growth in net profit[27]. - The company's total assets at the end of 2020 were CNY 1.18 billion, a 2.19% increase from 2019[24]. - The company's net cash flow from operating activities surged by 206.08% to CNY 127.34 million, driven by increased sales and reduced cash payments for goods[27]. - The company reported a total revenue of 18,910,000.00 RMB for the year, with a net profit of 16,970,962.18 RMB, indicating a slight increase in profitability compared to the previous year[81]. - The company's operating profit for the same period was 147.13 million yuan, showing a significant increase of 73.39% year-on-year[96]. - The company achieved a gross margin of 44.39% in the chemical raw materials and chemical manufacturing sector, an increase of 5.5 percentage points compared to the previous year[126]. Dividend Policy - The company plans to distribute a cash dividend of RMB 7 per 10 shares, totaling RMB 40,474,000, which accounts for 31.78% of the net profit attributable to shareholders for 2020[7]. - The cash dividend distribution is based on the share capital as of the dividend record date, with a proposed distribution of RMB 0.7 per 10 shares[185]. - The company has established a profit distribution policy prioritizing cash dividends, with a minimum of 80% for mature stages without major capital expenditures[181]. - The company's cash flow is deemed sufficient to support the proposed cash dividend without affecting its ongoing operations[181]. - The board of directors has approved the profit distribution plan, pending shareholder meeting approval for implementation[182]. Research and Development - Research and development expenses accounted for 4.24% of operating revenue, an increase of 0.66 percentage points compared to the previous year[25]. - The total R&D investment for the year was approximately ¥19.14 million, an increase of 31.68% compared to the previous year, representing 4.24% of total revenue[75][76]. - The company obtained 26 new intellectual property rights during the reporting period, including 8 invention patents and 17 utility model patents[73][74]. - The company has established collaborations with research institutions to enhance innovation and product development[73]. - The company is focusing on the development of molecular sieve catalysts for environmental governance, including products for coal-to-ethanol and diesel vehicle exhaust denitration[44]. Market Expansion and Strategy - The company aims to further optimize its sales structure and expand its market presence in the healthcare sector, particularly in oxygen production materials[26]. - The company is expanding its production capacity through projects like the "Adsorption Material Industrial Park Expansion Project" and the "Thailand Subsidiary Construction Project" to strengthen its market position[53]. - The company aims to expand its business into hydrogen purification, coal-based ethanol, and environmental remediation sectors, enhancing its product structure and market reach[178]. - The company is actively expanding its market presence in the environmental governance and energy chemical sectors, focusing on high-value-added product upgrades[98]. - The company has established a comprehensive innovation system and increased R&D investment to achieve breakthroughs in core technologies through independent research and development[42]. Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report[5]. - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[10]. Production and Capacity - The company's total production capacity is 93,000 tons per year, with a global market share of 4.43% in production and 4.24% in output for formed molecular sieves and activated molecular sieve powders in 2018, ranking sixth globally[53]. - The company has a production capacity of 31,000 tons of molecular sieve raw powder, 20,000 tons of formed molecular sieves, and 3,000 tons of activated molecular sieves, with an additional 10,000 tons of formed molecular sieve production line in trial production[53]. - The company completed the construction of a 4,500-ton oxygen-rich molecular sieve production line in the second quarter, and a 9,000-ton hydrogen and oxygen molecular sieve production line is in trial production[101]. - The company is focusing on expanding production capacity to meet increasing demand for molecular sieve products[129]. Customer Base and Sales - The company has established a stable customer base, including major domestic enterprises like Sinopec and international giants like Praxair[90]. - The company achieved sales revenue of 374.05 million yuan from molded molecular sieves, accounting for 82.84% of total revenue during the reporting period[101]. - The sales revenue from the oxygen production series reached 255.99 million yuan, representing 56.69% of total revenue, with a year-on-year growth of 39.26%[103]. - The sales of molded molecular sieves increased by 17.32%, contributing to a gross margin increase of 7.12 percentage points[128]. - The sales of molecular sieve raw powder decreased by 22.65%, resulting in a gross margin reduction of 6.94 percentage points[126]. Financial Management - The company faced risks related to raw material price increases, which could adversely affect performance if product prices do not adjust accordingly[118]. - The company is exposed to foreign exchange risks due to a significant portion of its business being export-oriented[118]. - The company's financial expenses decreased by 60.56%, reflecting improved cost management[123]. - The company benefited from an increase in the export tax rebate rate from 6% to 13% for its molecular sieve products, which positively impacted profitability[119]. - The company has maintained stable energy procurement costs, with natural gas prices down by 7.68% and electricity costs down by 3.86% year-on-year[168].

证券代码：688357 证券简称：建龙微纳 公告编号：2021-034 洛阳建龙微纳新材料股份有限公司 关于参加河南辖区上市公司 2021 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，洛阳建龙微纳新材料股份有限公司（以 下简称"公司"）定于 2021 年 6 月 8 日（周二）16:00-17:20 在线参加在全景网 举办的"真诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待 日活动。本次活动将采用网络远程的方式举行，投资者可登录"全景·路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司副总裁兼董事会秘书李怡丹女 士及相关工作人员（如有特殊情况，参会人员将可能进行调整）。本次活动中， 将主要就 2020 年度经营情况、公司发展战略等投资者所主要关心的问题进行沟 通交流。 欢迎广大投资者积极参与。 特此公告。 洛阳建龙微纳新材料股份有限公司董事会 2021 年 6 月 3 日 ...

Financial Performance - Net profit attributable to shareholders rose by 123.42% to CNY 32,831,979.69 year-on-year[6] - Operating revenue increased by 65.83% to CNY 125,436,139.42 compared to the same period last year[6] - Basic earnings per share increased by 128.00% to CNY 0.57 compared to CNY 0.25 in the same period last year[6] - The company reported a net profit of ¥237,987,708.04 for the first quarter of 2021, compared to ¥204,847,847.06 in the same period of 2020, marking an increase of approximately 16.1%[25] - Operating profit for Q1 2021 was ¥34,344,529.74, up 92.0% from ¥17,878,849.24 in Q1 2020[28] - The company reported a total profit of ¥37,728,129.74 for Q1 2021, up 121.5% from ¥17,027,535.03 in Q1 2020[28] - Comprehensive income for Q1 2021 totaled ¥30,606,635.29, significantly higher than ¥14,695,298.36 in Q1 2020[29] Cash Flow - The net cash flow from operating activities was CNY 50,777,671.14, a significant improvement from a negative CNY 2,703,474.01 in the previous year[6] - The company's cash flow from operating activities improved significantly, reaching RMB 50,777,671.14, compared to a negative cash flow of RMB -2,703,474.01 in the previous year[15] - In Q1 2021, the cash inflow from sales of goods and services reached ¥94,203,119.65, a significant increase of 111.7% compared to ¥44,621,914.19 in Q1 2020[35] - The total cash outflow for operating activities was ¥54,945,227.11, which is an increase from ¥48,118,375.09 in the previous year[36] - The ending balance of cash and cash equivalents was ¥126,968,233.89, compared to ¥85,590,041.55 at the end of Q1 2020, reflecting a year-over-year increase of 48.2%[36] Assets and Liabilities - Total assets increased by 2.58% to CNY 1,212,918,875.44 compared to the end of the previous year[6] - Contract assets decreased by 32.42% to RMB 5,020,910.77, primarily due to the expiration of certain warranty deposits[14] - Other current assets increased by 144.57% to RMB 633,172.18, mainly due to an increase in deductible input tax[14] - The company reduced its short-term borrowings by 66.67%, from RMB 30,000,000.00 to RMB 10,000,000.00, reflecting repayment of bank loans during the reporting period[14] - Current liabilities decreased to ¥189,897,969.73 from ¥195,312,750.19, a reduction of about 2.1%[24] - Non-current liabilities totaled ¥15,343,329.35, slightly down from ¥15,568,112.30, indicating a decrease of approximately 1.5%[20] - The total liabilities decreased to ¥205,241,299.08 from ¥210,880,862.49, a decline of about 2.5%[24] Research and Development - R&D investment accounted for 6.36% of operating revenue, up by 2.88 percentage points from the previous year[6] - Research and development expenses surged by 203.26% to RMB 7,980,224.07, driven by increased investment in ongoing projects and higher share-based payment costs for R&D personnel[15] - Research and development expenses increased to ¥7,980,224.07 in Q1 2021, up 203.0% from ¥2,631,445.93 in Q1 2020[27] Shareholder Information - The total number of shareholders reached 4,087 at the end of the reporting period[10] - The top shareholder, Li Jianbo, holds 24.82% of the shares, totaling 14,350,000 shares[10] Other Income and Expenses - Non-recurring gains and losses amounted to CNY 4,799,689.77, including CNY 5,000,000 from government subsidies[8][9] - Other income for Q1 2021 was ¥5,100,000.00, compared to ¥495,000.00 in Q1 2020, indicating a substantial increase[28] - The company experienced a credit impairment loss of ¥62,003.40 in Q1 2021, compared to a gain of ¥5,744.43 in Q1 2020[27]

Financial Performance - The company's operating revenue for 2020 was CNY 451,549,981.64, representing an increase of 11.23% compared to 2019[24]. - Net profit attributable to shareholders increased by 48.10% to CNY 127,370,724.24, while the net profit after deducting non-recurring gains and losses rose by 59.71% to CNY 109,229,410.44[24][26]. - The gross profit margin improved to 44.39%, up by 5.50 percentage points from the previous year[26]. - The net cash flow from operating activities surged by 206.08% to CNY 127,341,756.34, driven by increased sales and optimized sales structure[27]. - Basic earnings per share increased by 13.99% to CNY 2.20, reflecting the growth in net profit[27]. - The company achieved a total revenue of 451.55 million yuan in 2020, representing a year-on-year growth of 11.23%[98]. - The operating profit for the same period was 147.13 million yuan, showing a significant increase of 73.39% year-on-year[98]. - The company reported a total revenue of 18,910,000.00 RMB for the year, with a slight increase from 16,970,962.18 RMB in the previous year, representing a growth of approximately 5.5%[82]. Dividend Policy - The company plans to distribute a cash dividend of RMB 7 per 10 shares, totaling RMB 40,474,000, which accounts for 31.78% of the net profit attributable to shareholders for 2020[7]. - The cash dividend distribution policy prioritizes cash dividends, with a minimum of 80% for mature companies without significant capital expenditures[181]. - The company’s 2020 cash dividend proposal has been approved by the board and is pending shareholder approval[182]. - The company’s cash dividend policy is designed to protect the rights of minority investors[182]. - The company has established a profit distribution system to enhance transparency and operational feasibility[181]. Research and Development - Research and development expenses accounted for 4.24% of operating revenue, an increase of 0.66 percentage points from 2019[25]. - The total R&D investment for the year was approximately ¥19.14 million, an increase of 31.68% compared to the previous year[75]. - The total R&D expenditure accounted for 4.24% of the company's operating revenue, up from 3.58% in the previous year, indicating a growth of 18.44%[76]. - The company obtained 26 new intellectual property rights during the reporting period, including 8 invention patents and 17 utility model patents[73]. - The company has established several research and innovation platforms, including the "Henan Province Adsorption Molecular Sieve Engineering Technology Research Center" to drive product development[151]. Market and Industry Trends - The global zeolite market is expected to grow at a compound annual growth rate (CAGR) of 5.65% from 2020 to 2025, reaching a market size of $4.39 billion by 2025[46]. - The domestic zeolite industry is experiencing increased demand due to stricter environmental regulations and the push for carbon neutrality, with significant opportunities in VOCs treatment and nitrogen oxides pollution prevention[47][49]. - The market size for VOCs治理 in China was approximately 74.1 billion yuan in 2020, projected to exceed 130 billion yuan by 2025, reflecting a CAGR of 13%[50]. - The hydrogen energy sector is anticipated to create a market value of $2.5 trillion by 2050, with hydrogen production accounting for over 90% of hydrogen consumption in industrial applications[58]. Operational Risks and Compliance - The company has detailed various operational risks and corresponding mitigation measures in the report[5]. - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees[10]. - The company’s future plans and development strategies are subject to investment risks and do not constitute a commitment to investors[8]. Production and Capacity - The company has established a wholly-owned subsidiary in Thailand, expanding its international presence[13]. - The company's total production capacity is 93,000 tons/year, with a global market share of 4.43% in production capacity and 4.24% in output for molded molecular sieves and activated molecular sieve powders, ranking sixth globally[53]. - The company has a total capacity of 31,000 tons for molecular sieve raw powder, 20,000 tons for molded molecular sieves, and 3,000 tons for activated molecular sieves, with ongoing projects to expand production capacity[53]. - The company completed the construction of a 4,500-ton oxygen-rich molecular sieve production line in the second quarter, and a 9,000-ton efficient hydrogen and oxygen molecular sieve production line is in trial production[102]. Customer and Supplier Relations - The company has established a stable customer base, including major domestic enterprises like Sinopec and international giants like Praxair[91]. - The top five customers contributed 10,704.50 million RMB, accounting for 21.40% of the total annual sales[135]. - The top five suppliers accounted for 30.35% of the total annual purchases, with a total procurement amount of 9,952.78 million RMB[139]. Environmental and Sustainability Initiatives - The company emphasizes continuous innovation and has established a robust R&D capability to maintain competitiveness against international peers[35]. - The company’s strategic focus includes enhancing energy efficiency and environmental remediation, aligning with national policies on sustainable development[36]. - The company has implemented advanced environmental protection facilities, including a 4,000 t/d wastewater treatment plant and a 450 t/d MVR desalination facility[94]. Financial Position and Assets - The company’s cash and cash equivalents at the end of the period were 142,665,624.88 RMB, representing 12.07% of total assets[144]. - The total assets increased by 13.02% compared to the previous year, with fixed assets amounting to 351,455,661.48 RMB[144]. - The company reported a significant increase in deferred income tax assets, rising to CNY 2,549,053.73, up 49.64% from CNY 1,703,482.19[146]. Shareholder Commitments and Regulations - The company reported a commitment to not transfer or manage shares held prior to the IPO for 36 months from the date of listing[188]. - Shareholders are restricted from transferring more than 25% of their shares annually while serving as directors or senior management[189]. - The company has established a policy to ensure compliance with relevant laws and regulations regarding share transfers by directors and senior management[192].

2020 年第三季度报告 公司代码：688357 公司简称：建龙微纳 洛阳建龙微纳新材料股份有限公司 2020 年第三季度报告 1 / 32 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 14 | 2020 年第三季度报告 1.2 公司全体董事出席董事会审议季度报告。 一、 重要提示 1.3 公司负责人李建波、主管会计工作负责人张景涛及会计机构负责人（会计主管人员）于鲁杰 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 32 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 | 股东的扣除非经 | | | | | | --- | --- | --- | --- | --- | | 常性损益的净利 | | | | | | 润 | | | | | | 加权平均净资产 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2020, representing a year-on-year increase of 15%[13]. - The net profit attributable to shareholders was RMB 20 million, up 10% compared to the same period last year[13]. - The company's operating revenue for the first half of the year was ¥182,028,744.17, a decrease of 15.78% compared to ¥216,144,859.49 in the same period last year[20]. - Net profit attributable to shareholders increased by 2.51% to ¥50,780,164.83 from ¥49,538,152.50 year-on-year[20]. - The net profit after deducting non-recurring gains and losses rose by 13.32% to ¥41,981,514.66, driven by an improved sales structure and lower raw material prices, resulting in a gross margin increase to 46.66%, up 8.55% year-on-year[22]. - The net cash flow from operating activities increased by 31.00% to ¥41,837,644.22, attributed to an optimized sales structure and reduced cash payments for goods and services[22]. - Basic earnings per share decreased by 22.81% to ¥0.88 from ¥1.14 in the same period last year, primarily due to an increase in total shares outstanding from 43.36 million to 57.82 million[22]. - The weighted average return on equity decreased by 14.93 percentage points to 5.69% from 20.62% year-on-year[21]. - The company achieved a total R&D investment of ¥6,801,061.64, which represents 3.74% of its operating revenue[48]. - The company reported a total revenue of 16,760,000.00 RMB for the first half of 2020, with a net profit of 5,988,267.07 RMB[54]. Market Expansion and Product Development - Future outlook indicates a projected revenue growth of 20% for the second half of 2020, driven by new product launches and market expansion strategies[13]. - The company has expanded its user base by 25%, reaching a total of 50,000 active users[13]. - Market expansion efforts include entering two new regional markets, aiming for a 10% market share by the end of 2021[13]. - A new product line is expected to launch in Q4 2020, anticipated to contribute an additional RMB 15 million in revenue[13]. - The company is focusing on expanding its market presence through innovative product development and strategic patent acquisitions[47]. - The company is developing a "molecular sieve catalyst for diesel vehicle exhaust purification" with low production costs and environmental friendliness, aimed at meeting the National VI emission standards[40]. - The company has completed the construction of the "Annual Production of 4,500 Tons of Oxygen-Enriched Molecular Sieve Project," which enhances its leading position in the oxygen molecular sieve sector[69]. - The company is exploring market expansion opportunities through new product development and strategic partnerships in the chemical industry[54]. Research and Development - The company is investing RMB 30 million in R&D for new technologies related to molecular sieves and oxygen production systems[13]. - Research and development expenses accounted for 3.74% of operating revenue, an increase of 0.51 percentage points compared to the previous year[21]. - The company has established a comprehensive innovation system, increasing R&D investment to achieve breakthroughs in core technologies through both independent and collaborative research[34]. - The company has developed a new mixed cation molecular sieve technology that enhances nitrogen and oxygen separation efficiency[50]. - The company has applied for 12 invention patents and 9 utility model patents, which have been accepted for review[47]. - The company has multiple patented technologies in molecular sieve production, enhancing its competitive edge in the market[45]. - The company has collaborated with Jilin University to develop a specialized molecular sieve for soil improvement and heavy metal pollution remediation, showing promising results in field experiments[41]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[4]. - The company faces risks related to core competitiveness, including potential market share loss if competitors introduce more efficient products[71]. - The company is exposed to risks from raw material price increases, which could adversely affect its performance if product prices do not adjust accordingly[73]. - The company has ongoing significant litigation matters, but the outcomes are not expected to impact current or future profits[125]. Shareholder and Corporate Governance - The board of directors has approved a profit distribution plan, although no dividends will be issued for this period[6]. - The company has implemented strict compliance with shareholding commitments, including restrictions on share transfers for a specified period[92]. - The company has a lock-up period of 36 months for shares held before the IPO, during which no transfer or repurchase of these shares is allowed[93]. - The company must report any share reduction plans to the stock exchange 15 days prior to the first sale, with a maximum disclosure period of 6 months[101]. - The company guarantees that there are no fraudulent activities in the public offering of shares and listing on the Sci-Tech Innovation Board[112]. - The company will ensure the independence of its operations and will not misappropriate funds or resources[114]. - The company commits to maintaining the accuracy and completeness of its prospectus and other disclosure documents, bearing legal responsibility for any misrepresentation[115]. Environmental Initiatives - The company has established a wastewater treatment capacity of 4,000 tons per day and a solid waste closed storage site as part of its environmental protection initiatives[133]. - The company has implemented a dust collection system and a bag filter system to ensure that emissions meet standards, contributing to stable discharge of pollutants[133]. - The company has reduced production costs and environmental pollution by recycling certain by-products in the production of molecular sieve raw powder[134]. - The company has advanced environmental facilities, including a 4,000 tons/day wastewater treatment plant and a 450 tons/day MVR desalination facility, which help reduce production costs and pollution[63].

Financial Performance - Net profit attributable to shareholders was CNY 14,695,298.36, down 8.89% year-on-year[6] - Operating revenue for the period was CNY 75,641,368.95, representing an 18.13% decrease compared to the same period last year[6] - Basic earnings per share were CNY 0.25, a decline of 32.43% compared to CNY 0.37 in the same period last year[6] - Total operating revenue for Q1 2020 was ¥75,641,368.95, a decrease of 18.1% compared to ¥92,393,908.64 in Q1 2019[26] - Net profit for Q1 2020 was ¥14,695,298.36, a decline of 9.0% from ¥16,128,754.81 in Q1 2019[28] - Total profit for Q1 2020 was ¥17,027,535.03, a decrease of 8.7% from ¥18,644,988.15 in Q1 2019[26] Cash Flow - The net cash flow from operating activities was CNY -2,703,474.01, an improvement of 46.17% compared to the previous year[6] - Net cash flow from operating activities improved by 46.17% to CNY -2,703,474.01 due to a decrease in cash payments for goods and services[14] - Cash inflow from sales of goods and services in Q1 2020 was ¥44,621,914.19, a decrease of 14.4% compared to ¥52,124,280.46 in Q1 2019[34] - Net cash flow from operating activities in Q1 2020 was -¥2,703,474.01, an improvement from -¥5,022,541.57 in Q1 2019[35] - Cash inflow from investment activities in Q1 2020 totaled ¥450,509,643.56, with cash outflow of ¥488,328,573.43, resulting in a net cash flow of -¥37,818,929.87[36] - Cash inflow from financing activities in Q1 2020 was ¥20,000,000.00, compared to ¥9,000,000.00 in Q1 2019, marking a 122.2% increase[37] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,154,769,328.43, a decrease of 0.20% compared to the end of the previous year[6] - Total current assets as of March 31, 2020, were CNY 776,522,670.57, slightly down from CNY 778,922,433.02 at the end of 2019[18] - Total liabilities decreased from CNY 285,634,396.84 to CNY 268,681,107.03, a reduction of about 5.93%[20] - Current liabilities decreased from CNY 239,036,909.26 to CNY 222,196,833.72, a reduction of about 7.06%[20] - Non-current liabilities decreased from CNY 46,597,487.58 to CNY 46,484,273.31, a decline of approximately 0.24%[20] - Total liabilities reached ¥285,634,396.84, with current liabilities at ¥239,036,909.26 and non-current liabilities at ¥46,597,487.58[41] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,343[12] - The largest shareholder, Li Jianbo, held 14,350,000 shares, representing 24.8% of the total shares[12] Research and Development - Research and development expenses accounted for 3.48% of operating revenue, down 21.8% from 4.45% in the previous year[6] - R&D expenses decreased by 35.97% to CNY 2,631,445.93 based on the progress of R&D projects[14] - Research and development expenses for Q1 2020 were ¥2,631,445.93, a decrease of 36.0% from ¥4,109,500.54 in Q1 2019[26] Financial Adjustments and Standards - The company executed a new revenue recognition standard starting January 1, 2020, impacting financial reporting[42] - The company is not applying retrospective adjustments for prior comparative data under the new revenue standards[48] - The cumulative impact of the new revenue standards will adjust the financial statement amounts without altering comparable period data[48] - The company is committed to complying with the new accounting standards as mandated by the Ministry of Finance[48] Other Financial Metrics - The weighted average return on net assets decreased to 1.67%, down 76.87% from 7.22% in the previous year[6] - Management expenses increased by 53.04% to CNY 6,307,696.68 due to higher labor, social security, and employee welfare costs[14] - Other income for Q1 2020 was ¥113,214.27, a significant decrease from ¥844,444.27 in Q1 2019[26]